New Zealanders now waiting over 3 years for many new drugs

15 December 2015
new-zealand

New Zealanders are waiting for over 35 cost-effective medicines recommended by the country’s Pharmaceutical Management Agency PHARMAC’s technical advisory committee. The average waiting time is now over three years.

“Accessing the right medicines at the right time is crucial. The reality is that New Zealanders have been missing out on effective medicines for too long” said Graeme Jarvis, general manager of trade group Medicines New Zealand. It’s time to treat patients – not ask for patience, the trade group argues.

A recent report shows that investment in innovative medicines saved Australian taxpayers almost $7 billion in hospital costs, and saving over 140,000 years of life before the age of 75 for Australian patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical